Toxicity testing is required to evaluate compounds to identify their potential adverse effects, to assure safety for its human and environmental use. In vitro toxicity testing is ideally suited for the investigation of molecular, cellular, and physiological mechanisms of chemically induced toxicity, which cannot readily be studied in vivo. "
Visionary leaders are the leading market players in terms of new developments such as product launches, innovative technologies, and the adoption of growth strategies. These players have a broad product offering that caters to most of the regions globally. Visionary leaders primarily focus on acquiring the leading market position through their strong financial capabilities and their well-established brand equity.
Dynamic Differentiators are established players with very strong business strategies. However, they have a weaker product portfolio compared to the visionary leaders. They generally focus only on a specific type of technology related to the product.
Innovators in the competitive leadership mapping are vendors that have demonstrated substantial product innovations as compared to their competitors. The companies have focused on product portfolios. However, they do not have very strong growth strategies for their overall business, when compared with the visionary leaders.
Emerging companies have niche product and service offerings. Their business strategies are not as strong as that of the established vendors. The emerging vendors include the new entrants in the market, emerging in terms of product portfolio and geographic reach, and require time to gain significant traction in the market.
Best In Vitro Toxicology Testing Products
Cyprotex is a preclinical CRO. It specializes in ADME-Tox and Biosciences, including both in vitro (laboratory experiments) and in silico (computer modeling) approaches.It is one of the leaders in toxicology testing services. Cyprotex specializes in ADME-Tox and biosciences, including both in vitro and in silico approaches and relies heavily on its R&D arm to develop new products and services
Bio-Rad Laboratories, Inc. develops and markets clinical diagnostics systems, analytical devices, instruments, software, consumables, and reagents. Bio- Rad operates through 2 business segments - Life Sciences and Clinical Diagnostics. Clinical Diagnostics business segment supplies over 3,000 products that cover more than 300 clinical diagnostics tests. For in vitro toxicology testing, Bio-Rad offers reagents for cellular health analysis, cell imaging, assay kits for apoptosis and autophagy, and antibodies for flow cytometry.
The company operates through 3 segments—Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services The company also provides services through clinical supply services, like cell line engineering, pharmaceutical lab services, and impurity and structural characterization through mass spectrometry.
Ascendance also provides its proprietary in vitro micro-liver cell-based platforms for use in safety testing, and pharmaceutical, biotherapeutic, and diagnostic product development. The combination of Hepregen and ESI assets enables broadening of capabilities, allowing a world-class product development team to create new applications for its existing products and a suite of new products. The company offers cell-based assays for in-vitro toxicology testing and also provides services for predictive toxicology testing, mechanistic toxicology testing, and DMPK applications.
